Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for unresectable hilar cholangiocarcinoma
ChiCTR1900022746Phase 4Recruiting
- Sponsor
- Inner Mongolia Autonomous Region People's Hospital
- Start
- May 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hilar cholangiocarcinoma (HC), sponsored by Inner Mongolia Autonomous Region People's Hospital. Primary endpoint: Safety. Started May 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on ChiCTR1900022746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022746.